Pulmonx (LUNG)
(Delayed Data from NSDQ)
$7.44 USD
-0.04 (-0.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $7.45 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.44 USD
-0.04 (-0.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $7.45 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Zacks News
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 4.88% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
by Zacks Equity Research
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 5% and 9.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pulmonx Corporation (LUNG) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pulmonx Corporation (LUNG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Down 27.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Pulmonx Corporation (LUNG)
by Zacks Equity Research
Pulmonx Corporation (LUNG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 78.6% in Pulmonx Corporation (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.44% and 1.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Pulmonx Corporation (LUNG) Climb 117% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 117.5% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Privia Health (PRVA) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Pulmonx Corporation (LUNG) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 24.32% and -0.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.